
    
      Patients who have completed protocol FDA 103B are offered the option of receiving extended
      maintenance. Patients who have received no prior ddI are treated either with intravenous
      nystatin alone (at the same dose level administered in FDA 103B) or with a regimen of
      intravenous nystatin and ddI alternating on 3-week cycles. Treatment continues for 12 weeks.
    
  